Identification of cardiomyopathy associated circulating miRNA biomarkers in patients with muscular dystrophy using a complementary cardiovascular magnetic resonance and plasma profiling approach

Table 6 Plasma miRNA results in MD patients with normal vs. pathological CMR results

miRNA plasma levels^a (/10³)	Normal CMR	Abnormal CMR	p value
miRNA plasma levels^a (/10³)	N = 14	N = 49	p value
-206	14.36 (3.07–49.46)	21.76 (4.82–72.71)	0.68
-144-5p	8.94 (0.00–163.41)	9.85 (0.00–171.21)	0.97
-146b	84.15 (40.30–169.65)	38.75 (0.00–177.31)	0.25
-15b	7.44 (0.00–21.87)	0.00 (0.00–18.78)	0.43
-195	9.76 (1.53–19.84)	8.31 (0.57–21.25)	0.86
-20b	49.38 (29.88–79.03)	65.38 (19.43–86.37)	0.66
-21	71.91 (2.89–107.05)	11.48 (0.00–113.69)	0.61
-221	0.00 (0.00–35.26)	0.00 (0.00–11.27)	0.87
-222	1367.66 (689.45–1764.90)	2230.30 (964.52–5884.91)	0.09
-26a	173.94 (47.45–324.42)	326.81 (126.07–602.29)	0.63
-29a	0.00 (0.00–0.00)	0.00 (0.00–0.00)	0.94
-29c	0.00 (0.00–2.24)	0.00 (0.00–0.56)	0.93
-342	1987.68 (808.31–2723.93)	2639.34 (1333.85–5106.77)	0.16
-378a-3p	14.15 (0.00–273.74)	39.74 (5.89–290.67)	0.39
-378a-5p	17.32 (2.66–40.41)	39.29 (13.24–101.0)	0.06
-451	104.66 (57.69–312.21)	206.41 (110.79–338.52)	0.27
-93	24.46 (0.38–55.52)	26.95 (0.00–69.92)	0.93

(^a) – Each miRNA plasma level was normalized to miR-16 plasma levels and thereafter multiplied by 10³ in order to increase readability
Bold text indicates a significant p-value of <0.05

ISSN: 1532-429X